The Women’s Heart Health Summit, sponsored by the Cardiovascular Research Foundation, took place in New York City last week, bringing together both clinical experts on heart failure and peripheral disease as well as advocates in women’s heart to discuss the challenges present in our current system.
While heart disease is the number one killer of women in the U.S., public opinion and many women across the U.S. still believe breast cancer to be a greater threat, emphasizing the need for more education.
Report from the Women's Heart Health Summit: Increasing awareness for heart disease in women
With health care reform’s emphasis on avoiding hospital readmissions and the rising cost of chronic disease management, it is no surprise that heart failure has lately been the focus of a number of device trials, care coordination initiatives, and journal articles. However, as recent news suggests, researchers must be diligent in discerning which tools and therapies are most effective in managing this tricky patient population—both from a clinical and financial standpoint—given the sheer volume of solutions coming down the pike.
Two sides of the heart failure coin: Balancing costs versus treatment effectiveness
In a recent interview with Medical Physics Web, physicist Markus Roth of the Laser Ion Generation, Handling and Transport (LIGHT) project at the Technical University of Darmstadt, Germany, announced progress in the development of technology that could lower the cost, size, and complexity of ion sources used for clinical proton therapy radiation oncology delivery systems, and eventually replace those systems in 10 to 20 years.
Laser-based ion source could reduce size and expense of proton therapy systems